Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors
Aadi Bioscience, a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined […]
NHS Slashes Longest Elective and Cancer Patient Waiting Lists
The number of people waiting over 18 months for NHS care has fallen again despite […]
EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis
EVERSANA, a leading provider of commercialization services to the life science industry, today announced a […]
Medtronic to Boost AI Innovation with New Platform Introduction
Medtronic, a global leader in healthcare technology, has announced Cosmo Pharmaceuticals and NVIDIA plan to […]
PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate
PeptiDream, a public Kanagawa, Japan-based biopharmaceutical company, has today announced the nomination of the second […]
Lunit Meets MDR CE Requirements for 3D Breast Tomosynthesis AI Solution
Lunit, a leading global provider of AI-powered cancer solutions, today announced that its AI solution […]
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
Synaffix, a biotechnology company focused on commercializing its clinical-stage platform technology for the development of […]
DEM BioPharma Appoints Miriam Merad, M.D., Ph.D., to Scientific Advisory Board
DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and macrophages […]
Catamaran Bio Selects OmniaBio as Partner to Develop and Manufacture Allogeneic CAR-NK Cell Therapies
Catamaran Bio, a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, and OmniaBio, […]
Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more